Saltar al contenido
Merck

Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model.

Frontiers in pharmacology (2017-09-21)
Gabriele Pizzino, Natasha Irrera, Federica Galfo, Giacomo Oteri, Marco Atteritano, Giovanni Pallio, Federica Mannino, Angelica D'Amore, Enrica Pellegrino, Federica Aliquò, Giuseppe P Anastasi, Giuseppina Cutroneo, Francesco Squadrito, Domenica Altavilla, Alessandra Bitto
RESUMEN

Glucocorticoid-induced osteoporosis (GIO) is a secondary cause of bone loss. Bisphosphonates approved for GIO, might induce jaw osteonecrosis; thus additional therapeutics are required. Adenosine receptor agonists are positive regulators of bone remodeling, thus the efficacy of adenosine receptor stimulation for treating GIO was tested. In a preventive study GIO was induced in Sprague-Dawley rats by methylprednisolone (MP) for 60 days. Animals were randomly assigned to receive polydeoxyribonucleotide (PDRN), an adenosine A2 receptor agonist, or PDRN and DMPX (3,7-dimethyl-1-propargylxanthine, an A

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
3,7-Dimethyl-1-propargylxanthine, ≥98% (HPLC), powder